GSK (LON:GSK) Insider Emma Walmsley Purchases 7 Shares

GSK plc (LON:GSK) insider Emma Walmsley bought 7 shares of the company’s stock in a transaction on Thursday, October 9th. The stock was bought at an average price of GBX 1,641 per share, with a total value of £114.87.

Emma Walmsley also recently made the following trade(s):

• On Tuesday, September 9th, Emma Walmsley purchased 9 shares of GSK stock. The stock was acquired at an average cost of GBX 1,486 per share, for a total transaction of £133.74.
• On Monday, August 11th, Emma Walmsley purchased 9 shares of GSK stock. The stock was acquired at an average cost of GBX 1,408 per share, for a total transaction of £126.72.

GSK Stock Performance

Shares of GSK stock opened at GBX 1,625 on Friday. GSK plc has a 52 week low of GBX 1,242.50 and a 52 week high of GBX 1,684.50. The business’s fifty day simple moving average is GBX 1,488.36 and its 200-day simple moving average is GBX 1,439.31. The firm has a market cap of £65.40 billion, a PE ratio of 1,964.93, a price-to-earnings-growth ratio of 1.24 and a beta of 0.31. The company has a quick ratio of 0.73, a current ratio of 0.81 and a debt-to-equity ratio of 114.64.

GSK (LON:GSK) last announced its quarterly earnings results on Wednesday, July 30th. The company reported GBX 75.30 EPS for the quarter. GSK had a return on equity of 18.08% and a net margin of 8.02%. Equities analysts forecast that GSK plc will post 175.980975 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several brokerages have recently commented on GSK. JPMorgan Chase & Co. reaffirmed an “under review” rating on shares of GSK in a research note on Friday, October 3rd. Berenberg Bank reaffirmed a “hold” rating and issued a GBX 1,600 price target on shares of GSK in a research note on Friday, July 18th. Deutsche Bank Aktiengesellschaft reissued a “hold” rating and set a GBX 1,450 target price on shares of GSK in a research note on Thursday, July 31st. Finally, Shore Capital reissued a “buy” rating and set a GBX 2,100 target price on shares of GSK in a research note on Wednesday, August 27th. One analyst has rated the stock with a Buy rating and two have given a Hold rating to the company. Based on data from MarketBeat, GSK presently has a consensus rating of “Hold” and a consensus price target of GBX 1,637.50.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.